iRhythm Technologies, Inc. (IRTC)

US — Healthcare Sector
Peers: ITGR  CNMD  LIVN  HSKA  KIDS  NPCE  ELMD  SRDX  SGHT  GKOS  FNA  OFIX  NUVA  BRKR 

Automate Your Wheel Strategy on IRTC

With Tiblio's Option Bot, you can configure your own wheel strategy including IRTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IRTC
  • Rev/Share 19.5817
  • Book/Share 2.7434
  • PB 51.8475
  • Debt/Equity 8.4867
  • CurrentRatio 5.7121
  • ROIC -0.1339

 

  • MktCap 4541054672.0
  • FreeCF/Share 0.4414
  • PFCF 325.6871
  • PE -45.7005
  • Debt/Assets 0.7942
  • DivYield 0
  • ROE -1.1284

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade IRTC Wells Fargo Equal Weight Overweight -- $130 May 2, 2025
Resumed IRTC Wells Fargo -- Equal Weight -- $86 Dec. 3, 2024
Initiation IRTC Goldman -- Neutral -- $78 Oct. 4, 2024

News

iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know
IRTC
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive

iRhythm Technologies (IRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know
iRhythm Technologies, Inc. (IRTC) Q4 2024 Earnings Call Transcript
IRTC
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Neutral

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, IR Quentin Blackford - President & CEO Daniel Wilson - CFO Conference Call Participants Macauley Kilbane - William Blair Lilia-Celine Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Nathan Treybeck - Wells Fargo David Roman - Goldman Sachs Sam Eiber - BTIG Jon Young - Canaccord Genuity David Rescott - Baird Suraj Kalia - Oppenheimer Felipe Lamar - Truist Paige Chamberlain - Wolfe Research Operator Good afternoon. Thank you for attending today's iRhythm Technologies Q4 2024 Earnings Conference …

Read More
image for news iRhythm Technologies, Inc. (IRTC) Q4 2024 Earnings Call Transcript
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect
IRTC
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out
IRTC
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
IRTC
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation

About iRhythm Technologies, Inc. (IRTC)

  • IPO Date 2016-10-20
  • Website https://www.irhythmtech.com
  • Industry Medical - Devices
  • CEO Mr. Quentin S. Blackford
  • Employees 2000

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.